The YIA is a one-year grant totaling $50,000 that supports personnel and/or research expenses, and travel to attend the Conquer Cancer Grants & Awards Ceremony at the ASCO Annual Meeting. Applicants ...

American Society of Clinical Oncology (ASCO) and Egyptian Cancer Society (ECS) leaders signed a Memorandum of Understanding (MOU) on June 2, 2025, during ASCO’s 61st Annual Meeting. The MOU formally ...

If you are looking for non-scientific summaries for patients, please visit the Patient Information page. TAPUR Study Analysis Plan The TAPUR Study is a phase II, non-randomized, open-label clinical ...

Key Dates Save the Date! The next ASCO Breakthrough will take place June 25-27, 2026, in Singapore and online. Attend the Meeting in Person ASCO's Media Headquarters is where you can apply for media ...

Panel Question and Answer - ASCO ...

[177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized ...

The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur: On June 18, 2025, the Food and Drug Administration approved tafasitamab-cxix (Monjuvi, Incyte ...

The 2026 cycle opens July 1, 2025. All Conquer Cancer research grant applications are carefully reviewed and evaluated by an independent Grants Selection Committee (Committee) using consistent ...

ALEXANDRIA, Va. — Results from a multinational study found that using artificial intelligence (AI) assistance can help pathologists more accurately classify breast cancers with low levels of HER2 ...

“This is the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer to demonstrate that post-treatment exercise is both achievable and effective in improving ...

ALEXANDRIA, Va., and SUNNYVALE, Calif. – The American Society of Clinical Oncology (ASCO) and Google Cloud today announced a powerful collaboration to launch an AI-based ASCO Guidelines Assistant.

ASCO Perspective Quote "This trial raises an intriguing hypothesis: that the increasingly popular GLP-1 medications used to treat diabetes and obesity might offer some benefit in reducing the risk of ...